American biopharma focused on antiviral therapies
Scientists at Oxford have begun Phase I trials of a ChAdOx BDBV vaccine for Bundibugyo Ebola in healthy UK adults, with 620,000 doses stockpiled and partnerships for African trials. The trial monitors safety and immune response for a year as the outbreak expands in the Democratic Republic of Congo.
Companies like Kalshi are expanding prediction markets to biotech trials, linking drug trial outcomes to tradable contracts. Bloomberg and The Guardian report Kalshi’s pilot, its safeguards, and regulatory concerns, as markets push for open data on trial probabilities amid regulatory decisions.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Nigeria faces a humanitarian gap as PEPFAR funding cuts drive patients toward unproven Islamic remedies. While lenacapavir rollout offers hope in the UK, access gaps persist in low-income regions where cost and infrastructure block lifesaving care.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Uganda reports HIV prevalence stable at 5.9% with 1.496 million adults living with HIV; 85.3% know their status, 99.1% on treatment, 96.5% virally suppressed. In MENA, lenacapavir's global rollout shows affordability gaps and uneven access; six generic manufacturers will produce cheaper versions, but many countries remain excluded, raising concerns over reach of the prevention option.